CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

Belite Bio outlines February 12, 2027 PDUFA date for Tinlarebant in Stargardt disease following FDA priority review acceptance

FDA DecisionTinlarebantPositive
AI Analysis

Summary

Belite Bio announced FDA priority review acceptance of Tinlarebant for Stargardt disease with a PDUFA decision date of February 12, 2027.

Importance:7/10
Sentiment:
0.60
PDUFAPriority ReviewRegulatoryOphthalmologyStargardt disease

Read the original article

Published by Seeking Alpha Healthcare on August 13, 2026 11:18 PM

Read Original